SCYX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
SCYNEXIS Inc (SCYX) is not a strong buy at the moment for a beginner investor with a long-term strategy. The stock lacks clear bullish signals from technical indicators, trading sentiment, and proprietary trading signals. While the company has shown significant improvement in financial performance and has potential catalysts in its pipeline, the current price trend and lack of strong institutional or insider activity suggest holding off on investment until more definitive positive signals emerge.
The MACD is below zero and negatively contracting, indicating a bearish trend. RSI is neutral at 52.121, showing no clear momentum. Moving averages are converging, and the stock is trading near its pivot level of 0.757, with resistance at 0.804 and support at 0.71. Overall, the technical indicators do not suggest a strong buy signal.
Revenue for 2025 increased significantly to $20.6 million from $3.7 million in
Net loss narrowed substantially to $8.6 million in 2025 from $21.3 million in
SCY-247, a second-generation antifungal drug, is in Phase 1 clinical trials with topline data expected in the second half of
GSK's relaunch of BREXAFEMME could provide SCYNEXIS with up to $145.5 million in annual net sales milestones and royalties.
The stock price has dropped by 3.22% in the regular market, reflecting weak short-term sentiment.
Financials for Q3 2025 show a significant YoY revenue drop of -49.39%.
No significant insider or hedge fund activity, indicating a lack of strong institutional confidence.
Lack of recent congress trading data and no clear valuation metrics available.
In Q3 2025, revenue dropped by -49.39% YoY to $334,000. However, net income improved significantly to -$8.59 million, up 205.95% YoY. EPS also improved to -0.17, up 183.33% YoY. Gross margin remained stable at 100%. The company has shown strong improvement in profitability metrics despite a decline in revenue.
No specific analyst rating or price target changes provided in the data. Wall Street sentiment appears neutral based on the lack of significant trading trends or institutional activity.
